Altasciences Featured Content

  1. Drug-Drug Interaction Study On A Novel Cardiovascular Medication 9/17/2024

    Learn how Altasciences leveraged its expertise to design, recruit, and conduct complex DDI studies, assessing pharmacokinetic and pharmacodynamic impacts of co-administered drugs.

  2. CNS Drug Development: Integrated Solutions To Reduce Complexity 5/22/2024

    Understand how early engagement with a fully integrated and experienced CNS drug development partner can accelerate timelines by facilitating continuous data sharing and decision-making.

  3. Altasciences' Facilities Moving In Unison 2/20/2024

    With nine facilities across North America, explore our integrated, comprehensive solution for all your early-phase drug development needs and unique expertise.

  4. Partnering With An Integrated CRO/CDMO: 5 Things You Need To Know 1/9/2024

    Sponsors always ask, “Will the partnership save me time and money?” and “How can you streamline the complex development processes for me?” Get the answers to these questions and more.

  5. End-To-End CNS Drug Development Solutions 1/5/2024

    Altasciences' premier CNS Center of Excellence can help you seamlessly navigate early-phase drug development with expert solutions, saving up to 40% in time along the way.

  6. Five Reasons To Choose Canada For Your Clinical Trials 4/18/2023

    Understand the conduct of clinical trials in Canada and learn five key reasons why you should choose Canada for your next trial.

  7. Clinical Trials: Faster, Easier, Proactive 1/30/2023

    Why wait? We begin planning your clinical study while your preclinical safety assessment is ongoing to start your first-in-human trials sooner.

  8. One Integrated Solution For Meeting Early Drug Development Needs 1/26/2023

    Over 143 executives of biopharmaceutical companies provided insights in a survey to understand the challenges they face when outsourcing their early phase drug development programs.

  9. Ophthalmic End-To-End Drug Development Solutions 1/26/2023

    Overcome challenges and complexities in ophthalmic drug development by partnering with an integrated CRO/CDMO provider with extensive regulatory knowledge and scientific expertise.

  10. Building Your Early Phase Clinical Data From Protocol To Regulatory Submission 1/26/2023

    From the initial preclinical data, read why the plan to bring a drug to market is built upon the foundation of solid, reliable data that demonstrates safety in a human patient population.